Cangene/Hyal
Executive Summary
Cangene will not proceed with its offer to acquire the drug delivery company Hyal because "certain conditions of the transaction cannot be satisfied," Cangene announced Aug. 17. The Canadian firms entered into the merger agreement in early August (1"The Pink Sheet" Aug. 9, p. 26)